Source: Annual Congress 2005 - Pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. B. Thorens, J. Plojoux, J. D. Aubert (Geneva, Lausanne, Switzerland). Clinical and hemodynamic long term efficacy of sildenafil in primary pulmonary hypertension. Eur Respir J 2005; 26: Suppl. 49, 3618

Member's Comments

No comment yet.

Related content which might interest you: Long term benefit of sildenafil in patients with pulmonary hypertension Source: Annual Congress 2009 - Pulmonary circulation II Year: 2009 Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014 Clinical, functional and hemodynamic response after six months of sildenafil in patients with pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary circulation Year: 2007 Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 347s Year: 2007 Pulmonary arterial hypertension: Long term effects of oral ambrisentan on clinical status, exercise capacity and haemodynamics Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Long-term safety and efficacy of imatinib in pulmonary arterial hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012 Long-term safety and tolerance of ambrisentan in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 205s Year: 2005 Long-term treatment with oral sildenafil in addition to chronic prostacyclin therapy improves pulmonary hemodynamics and six minute walking test in patients with pulmonary arterial hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002 Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: The COMPASS-3 study Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models Year: 2011 Hemodynamical effects of metformin and sildenafil in the treatment of experimental pulmonary hypertension Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019 Long term use of imatinib in patients with severe pulmonary arterial hypertension Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010 Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension Source: Eur Respir J 2010; 36: 808-818 Year: 2010 Enhanced efficacy of combining imatinib with sildenafil in a rodent model of pulmonary arterial hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Long-term bosentan therapy improves exercise capacity and hemodynamics in sarcoidosis-associated pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Efficacy and safety of oral bosentan in patients with Down‘s syndrome and pulmonary arterial hypertension due to congenital heart disease Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Efficacy of epoprostenol treatment for pulmonary hypertension: hemodynamic and clinical improvement during the initial 8-month period Source: Eur Respir J 2001; 18: Suppl. 33, 325s Year: 2001 Long term effects of transitioning from sitaxsentan to ambrisentan in pulmonary arterial hypertension Source: Annual Congress 2010 - Pulmonary circulation III Year: 2010